Research on drug resistance mechanism of trastuzumab caused by activation of the PI3K/Akt signaling pathway

Wspolczesna Onkologia

Volumn 17, Issue 4, 2013, Pages 363-369

  Chen, Xi ^a   Wang, Han ^a   Ou Yang, Xue Nong ^a   Xie, Fang Wei ^a   Wu, Jing Jing ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Breast cancer cell; HER2 neu; LY294002; PI3K Akt; Trastuzumab

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84885995417     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.35292     Document Type: Article

References (18)

1. Debska S, Kusińska R, Czernek U, et al. Prognostic value of expression of intracellular and extracellular domains of HER2 in patients with HER2-possitive breast cancer. Wspolczesna Onkol 2011; 15: 267-73.
2. Cianfrocea M, Goldstein LJ. Prognostic and predictive factors in early- stage breast cancer. Oncologist 2004; 9: 606-616. (Pubitemid 39546402)
3. Singer CF, Köstler WJ, Hudelist G. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Binphys Acta 2008; 1786: 105-13.
4. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-84. (Pubitemid 47050487)
5. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402. (Pubitemid 47539306)
6. Park BH, Davidson NE. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell 2007; 12: 297-9. (Pubitemid 47539315)
7. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009; 69: 2191-4.
8. Faratian D, Sims AH, Mullen P, Kay C, Um I, Langdon SP, Harrison DJ. Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS One 2011; 6: e23772.
9. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010; 21: 255-62.
10. Wiczyńska B, Rolski J. Targeted therapy. Part I. Signalling by tyrosine kinase receptors. Wspolczesna Onkol 2007; 11: 331-6.
11. Krawczyk P, Mlak R, Powrózek T, Nicoś M, Kowalski DM, Wojas-Krawczyk K, Milanowski J. Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Wspolczesna Onkol 2012; 16: 401-6.
12. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005; 18: 250-9. (Pubitemid 40188633)
13. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132-41. (Pubitemid 34791085)
14. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-95. (Pubitemid 34214843)
15. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 707-17.
16. Crowder RJ, Ellis MJ. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway. Breast Cancer Res 2005; 7: 212-4. (Pubitemid 41387433)
17. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880-6. (Pubitemid 30159344)
18. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002; 94: 3127-34. (Pubitemid 34670495)